Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Memantine
Drug ID BADD_D01378
Description Initially approved by the FDA in 2013, memantine is an N-methyl-D-aspartate (NMDA) receptor antagonist used in the management of Alzheimer's Disease (AD). It is different from many other Alzheimer's Disease medications, as it works by a different mechanism than the cholinesterase enzyme inhibitors normally employed in the management of Alzheimer's disease [A1639]. Memantine blocks the effects of glutamate, a neurotransmitter in the brain that leads to neuronal excitability and excessive stimulation in Alzheimer's Disease [T556]. In 2010, it was estimated that 36 million people worldwide live with Alzheimer's Disease. In 2013, this number increased to 44 million. Almost doubling every 20 years, the prevalence of Alzheimer's Disease is predicted to reach 66 million by 2030 and to 115 million by 2050 [F4366]. In December 2013, the G8 dementia summit concluded that dementia should be considered a global priority with the objective of developing a cure or a disease-modifying therapy by the year 2025 [L5953, F4366].
Indications and Usage Memantine is used to manage moderate to severe Alzheimer's dementia [FDA label]. A more recent systemic review and meta-analysis [A177106] indicates that memantine is beneficial as a first line drug for the treatment of Alzheimer's dementia. Cholinesterase inhibitors may be added to memantine for further beneficial effects on behavioral symptoms and other symptoms of dementia [A177106].
Marketing Status approved; investigational
ATC Code N06DX01
DrugBank ID DB01043
KEGG ID D08174
MeSH ID D008559
PubChem ID 4054
TTD Drug ID D01JEU
NDC Product Code 72603-118; 24196-184; 60687-184; 65162-173; 0615-8192; 55154-4151; 62135-895; 0904-6506; 53746-169; 55111-597; 0904-6505; 65015-892; 53746-173; 60687-173; 62135-896; 65162-169; 70518-3297; 0615-8319; 55154-7637; 72603-119; 55111-596
UNII W8O17SJF3T
Synonyms Memantine | Memantin | 1,3-Dimethyl-5-aminoadamantane | 1-Amino-3,5-dimethyladamantane | Namenda | Ebixa | Memantine Hydrochloride | Axura | D-145 | D 145 | D145
Chemical Information
Molecular Formula C12H21N
CAS Registry Number 19982-08-2
SMILES CC12CC3CC(C1)(CC(C3)(C2)N)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Weight increased13.15.01.006--
Wheezing22.03.01.0090.000121%
Withdrawal syndrome19.07.06.023; 08.06.02.0120.000181%Not Available
Xerophthalmia14.12.03.002; 06.06.03.008--Not Available
Mental status changes19.07.01.0010.000483%Not Available
Mobility decreased15.03.05.023; 17.02.05.018; 08.01.03.0300.000302%Not Available
Musculoskeletal disorder15.03.05.0250.000121%Not Available
Hypoacusis04.02.01.006--
Performance status decreased08.01.03.0420.000121%Not Available
Brain oedema17.07.02.003; 12.01.10.0100.000483%
Red blood cell sedimentation rate increased13.01.03.001--Not Available
Psychomotor skills impaired19.22.01.002; 17.02.10.0050.000242%Not Available
General physical health deterioration08.01.03.0180.000810%Not Available
Balance disorder08.01.03.081; 17.02.02.0070.000906%Not Available
Lung cancer metastatic22.08.01.004; 16.19.02.0030.000181%Not Available
Dysstasia15.03.05.011; 08.01.03.089; 17.02.02.0120.000181%Not Available
Musculoskeletal chest pain22.09.01.001; 15.03.04.0120.000121%
Deep vein thrombosis24.01.02.0030.001148%Not Available
Central nervous system lesion17.02.10.0110.000121%Not Available
Malignant neoplasm progression16.16.01.0050.000665%Not Available
Acute coronary syndrome24.04.04.011; 02.02.02.015--Not Available
Lymphatic disorder01.09.01.003--Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Inappropriate antidiuretic hormone secretion05.03.03.001; 14.05.07.0010.000870%Not Available
Affect lability19.04.01.001--Not Available
Haemorrhage24.07.01.002--Not Available
Faecaloma07.01.03.0040.000242%Not Available
Pulmonary mass22.02.07.0040.000181%Not Available
Gaze palsy17.02.05.044; 06.05.02.0140.000121%Not Available
Breast cancer female21.05.01.011; 16.10.01.004--Not Available
The 15th Page    First    Pre   15 16 17 18    Next   Last    Total 18 Pages